RespireRx Pharmaceuticals Inc.
A leader in the discovery and development of treatments for conditions affecting millions of people but with few or poor options — obstructive sleep apnea, ADHD, epilepsy, chronic pain and recovery from spinal cord injury.
Two platforms
RespireRx is developing a pipeline of new drug products based on broad patent portfolios across two distinct drug platforms.
ResolutionRx
Compounds that target the body’s endocannabinoid system — in particular the re-purposing of dronabinol, an endocannabinoid CB1 and CB2 receptor agonist already approved by the FDA for other indications, for obstructive sleep apnea.
EndeavourRx
AMPAkines, positive allosteric modulators of AMPA-type glutamate receptors, and GABAkines, PAMs of GABAA receptors — two routes to restoring signalling in the central nervous system.
Pipeline
| Platform | Compound | Indication | Stage |
|---|---|---|---|
| ResolutionRx | dronabinol | Obstructive sleep apnea (OSA) | Phase 2 complete |
| EndeavourRx | CX1739 / CX717 | ADHD | Phase 2 complete |
| EndeavourRx | CX1739 | Spinal cord injury — bladder function | Phase 2 funded |
| EndeavourRx | CX717 / CX1739 | Opioid-induced respiratory depression | Phase 2A complete |
| EndeavourRx | KRM-II-81 | Epilepsy | Translational |
| EndeavourRx | KRM-II-81 | Chronic pain | Preclinical |
Stages are the ones the company states on its own pages and in its releases.
Why OSA
Dronabinol is being developed for obstructive sleep apnea, a sleep-related breathing disorder that affects an estimated 29 million people in the United States — and there are no approved drug treatments for it.
In the news
The company on video
Published by the company’s CFO. Click to play — the videos load from YouTube only after you press play.